1. Home
  2. WEA vs NKTX Comparison

WEA vs NKTX Comparison

Compare WEA & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Bond Fund Share of Beneficial Interest

WEA

Western Asset Bond Fund Share of Beneficial Interest

HOLD

Current Price

$10.75

Market Cap

130.2M

Sector

Finance

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.33

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEA
NKTX
Founded
2002
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
130.2M
132.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WEA
NKTX
Price
$10.75
$2.33
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$13.25
AVG Volume (30 Days)
30.0K
657.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.87%
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.16
$1.31
52 Week High
$11.44
$2.81

Technical Indicators

Market Signals
Indicator
WEA
NKTX
Relative Strength Index (RSI) 39.61 48.04
Support Level $10.65 $1.95
Resistance Level $10.87 $2.41
Average True Range (ATR) 0.11 0.17
MACD -0.01 -0.04
Stochastic Oscillator 32.58 20.49

Price Performance

Historical Comparison
WEA
NKTX

About WEA Western Asset Bond Fund Share of Beneficial Interest

Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: